Aridis Pharmaceuticals Receives Nasdaq Notice On Late Filing Of Its Form 10-Q
Portfolio Pulse from Happy Mohamed
Aridis Pharmaceuticals (NASDAQ:ARDS) received a notice from Nasdaq for not being in compliance with listing rules due to the late filing of its Form 10-Q for Q1 2023. The company is working to complete the filing and anticipates filing it as soon as possible.
May 25, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aridis Pharmaceuticals received a Nasdaq notice for late filing of its Form 10-Q for Q1 2023, which may negatively impact its stock price in the short term.
Aridis Pharmaceuticals received a notice from Nasdaq for not being in compliance with listing rules due to the late filing of its Form 10-Q for Q1 2023. This news may negatively impact the company's stock price in the short term as it indicates potential issues with the company's financial reporting and compliance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100